The primary goal of this on-demand activity is to better understand how to diagnose, manage and effectively treat patients with hepatorenal syndrome (HRS) and acute kidney injury (AKI) based on current guidelines and the latest clinical evidence.
More information
Learning objectives
Upon completion of this activity, participants should be able to:
- Define the types of HRS and proposed pathophysiology.
- Discuss the International Club of Ascites (ICA) criteria for the diagnosis and management of AKI in cirrhosis and apply these criteria in clinical practice.
- Explain the therapies for HRS +/- AKI and apply recommended treatment strategies to clinical practice.
Course directors and faculty
Sammy Saab, MD (CHAIR)
UCLA Pfleger Liver Institute Clinic
Los Angeles, California
David Bernstein, MD
Hofstra Northwell School of Medicine
Roslyn, New York
Catherine Frenette, MD
Scripps MD Anderson Cancer Center
La Jolla, California
Marcelo Kugelmas, MD
South Denver Gastroenterology
Englewood, Colorado
Pricing
|
Member
|
Nonmember
|
| $Free |
$Free |
Sammy Saab, MD
Speaker Bureau: AbbVie, Bristol Myers Squibb, Bayer, Elsai, Exelixis, Gilead, Intercept, Salix
Advisor: AbbVie, Bayer, Eisai, Exelixis, Gilead, Intercept, Mallinckrodt, Salix
Honorarium Recipient: AbbVie, Bristol Myers Squibb, Bayer, Eisai, Exelis, Gilead Intercept, Mallinckrodt, Salix
David Bernstein, MD
Research Support: Bausch, Enanta, Gilead, GSK, La Jolla, Novo Dordisk, Novartis, Syneos, Pfizer, Protogonist
Consultant: AbbVie, Dova, Gilead, Shionosi
Catherine Frenette, MD
Speakers Bureau: AbbVie, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Gilead, Intercept, Salix, Shionogi
Consultant: Bayer, Conatus, Eisai, Genentech, Merck
Research Support: Bayer, Conatus, Genfit, Merck
Advisory Board: Gilead, Eisai, Exelixis, Genentech, Merck, Wako
Marcelo Kugelmas, MD
Consultant: Mallinckrodt
